Systemically administered interferon alfa-2a prevents recurrence of condylomata acuminata following CO2-laser ablation. The influence of the cyclic low-dose therapy regimen. Results of a multicentre double-blind placebo-controlled clinical trial.
Gross
G
G
Roussaki
A
A
Baur
S
S
Wiegand
M
M
Mescheder
A
A
D000293:Adolescent; D000328:Adult; D000368:Aged; D000998:Antiviral Agents / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D003218:Condylomata Acuminata / Q000517:prevention & control* / Q000601:surgery; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use*; D053685:Laser Therapy / Q000379:methods*; D008297:Male; D008875:Middle Aged; D011994:Recombinant Proteins; D012008:Recurrence
D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins